-
AIDSVAX is an
experimental HIV
vaccine that was
developed originally at
Genentech in San Francisco, California, and
later tested by the
VaxGen company...
-
vaccine - VaxGen:
AIDSVAX,
AIDSVAX B/B,
AIDSVAX B/E, HIV gp120
vaccine - Genentech, HIV gp120
vaccine AIDSVAX - VaxGen, HIV
vaccine AIDSVAX - VaxGen". Drugs...
- the 1990s,
VaxGen developed and
began trials of an AIDS
vaccine called AIDSVAX. The
National Institute of
Allergy and
Infectious Diseases (NIAID) worked...
-
AIDSVAX B/E was a component,
along with ALVAC, of the RV 144
vaccine trial in
Thailand that
showed partial efficacy in
preventing HIV. The
AIDSVAX B/E...
- Prayura; Kim,
Jerome H. (December 3, 2009). "Vaccination with
ALVAC and
AIDSVAX to
Prevent HIV-1
Infection in Thailand". New
England Journal of Medicine...
- Experiment,
London Sunday Times, 3
October 1999
Vaccine has no impact;
AIDSVAX's failure a blow to
treatment VaxGen Announces Changes to
Management and...
- Prayura; Kim,
Jerome H. (December 3, 2009). "Vaccination with
ALVAC and
AIDSVAX to
Prevent HIV-1
Infection in Thailand". New
England Journal of Medicine...
-
Buchbinder S;
Mastro TD;
Judson F;
Gorse GJ; et al. (July 2003).
VaxGen AIDSVAX B/B
Vaccine Trial: Recruitment, Demographics, and
Changes in Risk Behaviors...
- prime-dose
regimen with
canarypox ALVAC-HIV (vCP1521)
vaccine and HIV-1 gp120
AIDSVAX B/E was
found to be safe, well
tolerated and 31.2%
effective for the prevention...
- Premsri, N; Namwat, C; de Souza, M (2009-12-03). "Vaccination with
ALVAC and
AIDSVAX to
Prevent HIV-1
Infection in Thailand". N Engl J Med. 361 (23): 2209–2220...
